# How a Paid Activist Group Destroyed the Fight for Legal MDMA - 5CAST (#12) ft. Hamilton Morris Source: https://www.youtube.com/watch?v=EcD7m11yvEo Recap page: https://rapidrecap.app/video/EcD7m11yvEo Generated: 2025-09-27T15:31:57.027+00:00 --- ## Quick Overview A paid activist group called Symposia, allegedly funded by the pharmaceutical company Eona, successfully interfered with the FDA's plan to legalize MDMA for PTSD therapy after clinical trials showed high remission rates, primarily by launching a multi-year cancel campaign against figures in the MDMA world using progressive language to attack progressive causes. **Key Points:** - The FDA advisory panel pulled the plug on MDMA legalization for PTSD therapy following external pressure from Symposia, despite clinical trials showing around 80% of participants achieving significant remission. - Hamilton Morris highlights the extreme and contradictory behavior of core Symposia members, including one who allegedly advised engaging in "terrorist tactics" against Eona's competitor, Compass. - Symposia's campaign utilized accusations like "gentrification of consciousness," sexual misconduct claims, and cultural appropriation, often rooted in what Morris calls the "entrepreneurship of psychedelic negativity." - Eona, funded by biotech company Promega, allegedly used Symposia and a specific Vice blogger, Shayla Love, to spread negative press about its competitor, Compass, while simultaneously incentivizing MAPS to halt drug policy reform work. - The activist group Symposia ultimately self-destructed due to internal accusations of impropriety, proving the danger of funding "uncontrollable" and "seriously insane" extremist groups for corporate bidding. - Morris details his own history with Vice, noting its pivot from a counterculture literary magazine under Jesse Pearson to a news entity where fact-checking prioritized limiting legal liability over establishing truth, making it a "perfect tool" for Eona's disinformation. - MDMA therapy trials, arranged by MAPS and led by Rick Doblin, showed 67% of participants losing their PTSD diagnosis after just a few sessions, but the process was derailed partly due to an isolated incident of therapist sexual abuse and external sabotage. **Context:** The discussion centers on the collapse of the effort to legalize MDMA for PTSD treatment, featuring guest Hamilton Morris, a documentarian and chemist known for his work on psychoactive drugs including his series "Hamilton's Pharmacopia." The conversation focuses on the role of a specific activist organization, Symposia, and its alleged financial ties to the pharmaceutical company Eona, which contrasted sharply with the positive clinical outcomes achieved by MAPS (Multidisciplinary Association for Psychedelic Studies) in their MDMA trials. ## Detailed Analysis The video analyzes how the movement for legal MDMA-assisted therapy for PTSD was sabotaged by a paid activist group named Symposia, allegedly financed by the pharmaceutical company Eona. Despite MAPS clinical trials showing that 67% of participants lost their PTSD diagnosis after therapy, the FDA advisory panel rejected the proposal due to external pressure. Hamilton Morris details that Symposia engaged in a multi-year campaign using anti-capitalist and progressive language to attack MDMA legalization advocates, particularly Eona's competitor, Compass. Morris provides evidence that Eona representatives, including Bob Jesse, secretly funded Symposia's leader, David Nichols, who then advocated for "terroristic tactics" against Compass. Furthermore, Eona allegedly used the Vice blogger Shayla Love to disseminate false narratives suggesting Compass was interfering with legalization efforts in Oregon, when Eona was actually the entity providing financial incentives to MAPS to cease drug policy reform. Morris notes that this entire operation was built upon the "entrepreneurship of psychedelic negativity," characterized by moralistic hand-wringing over issues like the "gentrification of consciousness" and irrelevant patent scares, which distracted from the real issue: federal Schedule I prohibition. The segment concludes that funding extremist groups like Symposia, who were ultimately "uncontrollable" and turned on each other, proved to be a historically predictable failure for Eona's corporate strategy. ### Guest Introduction and Work - Hamilton Morris discusses his decade-long documentary work on psychoactive drugs and his current independent chemistry projects, including creating new LSD-type molecules funded via Patreon - Morris expresses admiration for Timothy Leary despite modern criticism and notes the failure of legacy media to seriously cover drug issues despite high overdose tolls. ### The Psychedelic Negativity Microeconomy - Morris identifies a trend of negative reporting driven by figures exploiting fears around concepts like the "gentrification of consciousness" and patenting of medicines, which distracts from fundamental issues like federal prohibition. ### The Symposia Scandal and Eona Influence - Symposia, described as collecting the "dregs of the psychedelic world," was allegedly paid by Eona (via the Sarlo family foundation and direct contributions from Eona's Bob Jesse) to run a campaign against Compass, including advocating for militant action to disrupt their business operations. ### MDMA Legalization Setback - The rejection of MDMA for PTSD therapy followed decades of work by Rick Doblin of MAPS, who implemented stringent protocols to prevent therapist abuse; the setback is attributed to external pressure from the Eona-backed Symposia campaign. ### Media Complicity and Ethics - Morris criticizes Vice for being an uncritical tool for Eona's narrative dissemination, contrasting it with an earlier era of Vice journalism under Jesse Pearson; he also notes how mainstream fact-checking often serves only to limit legal liability rather than establish truth.